Renger John 4
4 · Cerevel Therapeutics Holdings, Inc. · Filed Oct 6, 2022
Insider Transaction Report
Form 4
Renger John
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2022-10-04$10.28/sh+14,982$154,015→ 27,704 total - Sale
Common Stock
2022-10-04$30.00/sh−25,000$750,000→ 2,704 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-10-04−14,982→ 119,933 totalExercise: $10.28Exp: 2029-04-02→ Common Stock (14,982 underlying) - Exercise/Conversion
Common Stock
2022-10-04$3.50/sh+10,018$35,063→ 12,722 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-10-04−10,018→ 70,128 totalExercise: $3.50Exp: 2029-04-02→ Common Stock (10,018 underlying)
Footnotes (2)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2021 adopted by the Reporting Person.
- [F2]25% of the shares subject to this option vested and became exercisable on April 8, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.